Removing barriers to the distribution of life-saving vaccines

Apr 04, 2008

Barriers to the distribution of life saving vaccines in low income countries can and should be overcome, say experts in this week’s issue of the BMJ.

They suggest that building local clinical research and vaccine production capacity in developing countries will increase the global availability of affordable vaccines.

Delay in delivering vaccines in low and middle income countries results in more than two million deaths a year.

Many of the reasons offered for the unequal access to vaccines in poorer countries can be challenged with new evidence and a better understanding of the underlying problems, write Dave Chokshi, from the University of Pennsylvania School of Medicine and Aaron Kesselheim, from the Division of Pharmacoepidemiology anfd Pharacoeconomics at Brigham and Women’s Hospital.

They point out that an exclusive focus on the primacy of public health infrastructure can result in a missed opportunity to build infrastructure through vaccination. Studies of polio eradication in the Americas have shown how immunisation programmes can strengthen the infrastructure of health systems.

Vaccines are one of the few interventions that can save lives even when healthcare infrastructure is inadequate or non-existent, they argue.

However, there are worries about insufficient funding, say the authors. For instance, the Global Alliance for Vaccines and Immunization (GAVI) has collected almost $7bn since its inception in 2000, but it estimates that it will cost $35bn to carry out its existing programmes in the 72 poorest countries up to 2015.

In addition, there are concerns about intellectual property rights slowing the distribution of vaccine technology from rich to poor countries, prices offered by pharmaceutical manufacturers being too high, and the implementation of donation programmes being too slow.

So what needs to be done to increase the availability of these life saving vaccines, ask the authors?

Constructing clinical research of vaccine efficiency in low and middle income countries would expand scientific capacity, encourage more ethical clinical trials, and better inform government’s risk-benefit calculations for investing in vaccines, claim the authors.

In addition, lowering the barriers to vaccine production in developing countries by, for example, improving local manufacturers' access to specialised technology, would build innovative capacity as well as production capacity, they say.

But the authors believe that the ultimate aim of any effort to improve global access to vaccines is to show the benefits of vaccination to local leaders in health care and government.

Local political leadership when combined with increased investment can prioritise disease prevention, raise awareness of the benefits of vaccination, and encourage country-level leadership, they conclude.

Related Stories

Today's Australians are, by far, the best educated cohort in our history –- on paper, anyway -– but this is not reflected in the quality of our political discourse. We appear to be lacking in courage, ...

Research!America urges the 114th Congress to take action on five science priorities in the first 100 days of the legislative session in order to elevate research and innovation on the nation's agenda. The five priorities: ...

At least one dengue vaccine could be licensed within the next 4 years, as manufacturers are speeding up the development process for multiple dengue vaccine candidates in collaboration with health authorities and developing ...

43 billion Indian rupee (£4.4 billion) worth of fruit and vegetables wasted annually in India could be better conserved if the country had a sustainable cold chain of refrigerated warehousing and transport, say University ...

What do pacemakers, prosthetic limbs, Iron Man and flu vaccines all have in common? They are examples of an old idea that's been gaining in significance in the last several decades: transhumanism. The word ...

Environmental geographer Ruth DeFries is a pioneer in the study of how humans have transformed the surface of the Earth. Using satellite data, she explores how changes in Earth's vegetation can affect climate, ...

Recommended for you

(HealthDay)—About 6.1 percent of U.S. allopathic medical school seniors in the National Resident Matching Program (NRMP) were not placed into first-year residency positions, with a higher percentage of ...

Intensive care units across the United States vary widely in how they manage the care of patients who have set preexisting limits on life-sustaining therapies, such as authorizing do-not-resuscitate (DNR) orders and prohibiting ...

A new study highlights the best way to use kidneys from older deceased donors, providing the most benefits to patients and addressing the worsening organ shortage. The study's findings, which appear in an upcoming issue of ...

Fourteen European nations signed Wednesday in Spain the first ever international treaty to fight human organ trafficking, a business that generates over one billion dollars in illegal profits worldwide every year.

User comments : 0

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.